4种细胞因子在桥本甲状腺炎和甲状腺乳头状癌中的表达及相关性研究

周蕾; 黄学双; 李慧敏; 金鑫; 王海

doi:10.16766/j.cnki.issn.1674-4152.003601

4种细胞因子在桥本甲状腺炎和甲状腺乳头状癌中的表达及相关性研究

doi: 10.16766/j.cnki.issn.1674-4152.003601

周蕾¹,
黄学双²,
李慧敏³,
金鑫³,
王海^3, ,

1.
杭州市儿童医院检验科，浙江杭州 310006
2.
温州医科大学检验医学院, 浙江温州 325035
3.
浙江省立同德医院检验科，浙江杭州 310003

基金项目:

浙江省基础公益研究计划项目 LGF22H160047

详细信息

通讯作者:
王海, E-mail：wanghai.5188@163.com

中图分类号: R581.4 R736.1 R446
计量
- 文章访问数: 21
- HTML全文浏览量: 15
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2023-11-23
- 网络出版日期: 2024-09-05

Expression and correlation of four kinds of cytokines in patients with Hashimoto's thyroiditis or papillary thyroid carcinoma

1.
Department of Laboratory, Hangzhou Children's Hospital, Hangzhou, zhejiang 310006, China

摘要

摘要: 目的分析血清白细胞介素-2(IL-2)、白细胞介素-12p70(IL-12P70)、白细胞介素-10(IL-10)、白细胞介素-17(IL-17)在桥本甲状腺炎(HT)和甲状腺乳头状癌(PTC)中的表达差异，探讨4种细胞因子在HT和PTC中的作用。方法选取2022年7月—2023年6月浙江省立同德医院收治的HT患者30例(HT组)，PTC患者35例(PTC组)，健康体检者30例(对照组)。采用流式免疫荧光发光法检测各组血清IL-2、IL-12P70、IL-10、IL-17的水平。结果与对照组比较，PTC组患者血清IL-2、IL-12P70、IL-17显著升高(P < 0.05)，HT组血清IL-2、IL-12P70、IL-17升高，IL-10降低，差异有统计学意义(P < 0.05)。与HT组比较，PTC组血清IL-10显著升高[(9.46±2.22)pg/mL vs. (7.44±1.97)pg/mL，P < 0.05]。HT组甲状腺过氧化物酶抗体(TPOAb)与IL-10呈负相关关系，与IL-17呈正相关关系(P＜0.05)，甲状腺球蛋白抗体(TgAb)与IL-10呈负相关关系(P＜0.05)。采用甲状腺全切除与采用患侧腺体合并峡部切除的PTC患者术后血清IL-2、IL-12P70、IL-10、IL-17比较差异均无统计学意义(P>0.05)。结论 PTC患者和HT患者血清IL-2、IL-12P70、IL-17高表达，同时HT患者血清IL-10低表达，并与TPOAb和TgAb存在一定的相关性。采用甲状腺全切除和患侧腺体合并峡部切除的PTC患者术后4种细胞因子水平无显著变化。
- 桥本甲状腺炎 /
- 甲状腺乳头状癌 /
- 白细胞介素-2 /
- 白细胞介素-12P70 /
- 白细胞介素-10 /
- 白细胞介素-17
Abstract: Objective To analyzed the expression of serum Interleukin-2 (IL-2), Interleukin 12 P70 (IL-12P70), interleukin-10 (IL-10) and interleukin-17 (IL-17) in Hashimoto's thyroiditis carcinoma (HT) and papillary thyroid carcinoma (PTC), to investigate the role of 4 kinds of cytokines in HT and PTC. Methods Thirty patients with Hashimoto's thyroiditis, 35 patients with papillary thyroid carcinoma, and thirty healthy individuals were selected from Tongde Hospital of Zhejiang Province from July 2022 to June 2023. They were divided into HT group, PTC group, and healthy control group. The serum levels of IL-2, IL-12P70, IL-10, and IL-17 were detected by flow cytometry. Results Compared with the healthy control group, the serum levels of IL-2, IL-12P70, and IL-17 were significantly higher in both the PTC and HT groups (P < 0.05). Compared with the HT group, the serum level of IL-10 was significantly increased in the PTC group [(9.46±2.22) pg/mL vs. (7.44±1.97) pg/mL, P < 0.05]. In the HT group, thyroid peroxidase antibody (TPOAb) levels were negatively correlated with the level of IL-10 and positively correlated with the level of IL-17 (P < 0.05). The level of thyroglobulin antibody (TgAb) was negatively correlated with the level of IL-10 (P < 0.05). The levels of IL-2, IL-12P70, IL-10, and IL-17 in thyroid tumor patients showed no significant differences after total thyroidectomy or thyroid gland with isthmus resection(P>0.05). Conclusion The serum levels of IL-2, IL-12P70, and IL-17 elevated in PTC and HT patients, while the serum levels of IL-10 decreased in HT patients and correlated with TPOAb and TgAb levels. There were no significant changes in the levels of these cytokines after total thyroidectomy or thyroid gland with isthmus resection in patients with PTC.
- Hashimoto's thyroiditis /
- Thyroid cancer /
- IL-2 /
- IL-12P70 /
- IL-10 /
- IL-17

HTML全文

表 1 3组研究对象TPOAb和TgAb测定值(x±s，IU/mL)

Table 1. Vaules of TPOAb and TgAb among three groups of subjects (x±s, IU/mL)

组别	例数	TPOAb	TgAb
对照组	30	5.53±1.66	7.48±2.46
HT组	30	515.69±304.66	178.13±137.75
PTC组	35	589.68±421.32	219.46±155.43

下载: 导出CSV

表 2 3组研究对象血清IL-2、IL-12P70、IL-10、IL-17比较(pg/mL)

Table 2. Comparison of serum IL-2, IL-12P70, IL-10, and IL-17 among three groups (pg/mL)

组别	例数	IL-2 [M(P₂₅, P₇₅)]	IL-12P70 [M(P₂₅, P₇₅)]	IL-10 (x±s)	IL-17 (x±s)
对照组	30	0.21(0.08, 0.35)	0.08(0.04, 0.14)	10.65±2.87	5.65±1.88
HT组	30	1.15(0.38, 1.77)^a	0.77(0.36, 1.16)^a	7.44±1.97^a	8.22±2.96^a
PTC组	35	1.02(0.34, 1.73)^a	0.76(0.33, 1.10)^a	9.46±2.22^c	8.32±3.13^a
统计量		13.835^b	8.550^b	14.037^d	9.429^d
P值		< 0.001	< 0.001	< 0.001	< 0.001
注：与对照组比较，^aP < 0.05；与桥本甲状腺炎组比较，^cP < 0.05；^b为H值，^d为F值。

下载: 导出CSV

表 3 不同手术方案PTC组患者术前术后4种细胞因子比较(pg/mL)

Table 3. Comparison of 4 cytokines before and after surgery in PTC group with different surgical plans (pg/mL)

手术方法	例数	IL-2[M(P₂₅, P₇₅)]			IL-12P70[M(P₂₅, P₇₅)]
手术方法	例数	术前	术后	术前-术后的差值	术前	术后	术前-术后的差值
甲状腺全切除	13	1.06(0.46, 1.59)	1.00(0.49, 1.43)	0.34(0.11, 0.59)	0.74(0.36, 1.16)	0.65(0.31, 0.99)	0.28(0.13, 0.44)
患侧腺体合并峡部切除	22	0.97(0.47, 1.41)	0.96(0.47, 1.46)	0.31(0.13, 0.51)	0.79(0.39, 1.23)	0.72(0.34, 1.10)	0.25(0.12, 0.42)
统计量		0.235^a	0.363^a	1.242^a	-0.401^a	-0.289^a	1.868^a
P值		0.847	0.764	0.227	0.739	0.782	0.075

手术方法	例数	IL-10(x±s)			IL-17(x±s)
手术方法	例数	术前	术后	术前-术后的差值	术前	术后	术前-术后的差值
甲状腺全切除	13	9.56±2.27	9.34±2.32	1.48±0.47	8.01±2.93	7.83±2.84	1.33±0.39
患侧腺体合并峡部切除	22	9.70±2.47	9.41±2.36	1.67±0.52	7.97±3.01	7.51±2.97	1.59±0.46
统计量		0.184^b	0.461^b	-1.081^b	0.038^b	0.332^b	-1.705^b
P值		0.855	0.656	0.291	0.969	0.768	0.103
注：^a为Z值，^b为t值。

下载: 导出CSV

表 4 HT组TPOAb、TgAb与4种细胞因子水平的相关性分析

Table 4. Correlation analysis of the levels of TPOAb and TGAb with the levels of four cytokines in the HT group

项目	IL-2		IL-12P70		IL-10		IL-17
项目	r值	P值	r值	P值	r值	P值	r值	P值
TPOAb	0.261	0.122	0.328	0.071	-0.463	＜0.001	0.385	0.003
TgAb	0.336	0.081	-0.297	0.231	-0.591	＜0.001	0.303	0.078

下载: 导出CSV

参考文献(18)

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12): 1164-1201. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZF202112014.htm Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology(CSCO)Differentiated Thyroid Cancer[J]. Journal of Cancer Control And Treatment, 2021, 34(12): 1164-1201. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZF202112014.htm
[3]	傅莉萍, 金剑虹, 王保法, 等. 骨化三醇对桥本甲状腺炎患者TPOAb、TgAb、Th17/Treg相关细胞因子的影响[J]. 浙江医学, 2019, 41(22): 2398-2401. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJYE201922015.htm FU L P, JIN J H, WANG B F, et al. Impact of calcitriol on the thyroid peroxidase antibody, thyroglobulin antibody levels and Th17/Treg related cytokines in serum of patients with Hashimoto's thyroiditis[J]. Zhejiang Medical Journal, 2019, 41(22): 2398-2401. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJYE201922015.htm
[4]	田文. 甲状腺乳头状癌诊治之中国经验与未来走向[J]. 临床外科杂志, 2020, 28(3): 201-204. TIAN W. The Chinese experience and future trend of thyroid cancer diagnosis and treatment[J]. Journal of Clinical Surgery, 2020, 28(3): 201-204.
[5]	朱旭东. 桥本氏甲状腺炎患者血清TPOAb、TgAb水平与病情的相关性分析[J]. 检验医学, 2018, 33(10): 903-906. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYY201810009.htm ZHU X D. Serum TPOAb and TgAb levels in Hashimoto's thyroiditis patients and their correlations with disease severity[J]. Laboratory Medicine, 2018, 33(10): 903-906. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYY201810009.htm
[6]	VARRICCHI G, LOFFREDO S, MARONE G, et al. The immune landscape of thyroid cancer in the context of immune checkpoint inhibition[J]. Int J Mol Sci, 2019, 20(16): 3934. DOI: 10.3390/ijms20163934.
[7]	朱冯赟智, 王茜, 何菁, 等. 白介素-2及其受体在自身免疫病发病中作用的研究进展[J]. 中国免疫学杂志, 2023, 39(4): 842-848. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXZ202304029.htm ZHU F Y Z, WANG X, HE J, et al. Advances on role of interleukin-2 and its receptors in development of autoimmune diseases[J]. Chinese Journal of Immunology, 2023, 39(04): 842-848. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMXZ202304029.htm
[8]	张滢, 梁楠, 孙辉. 细胞因子与甲状腺乳头状癌: 从分子机制到临床应用的研究现状[J]. 中国实验诊断学, 2022, 26(1): 117-120. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD202201035.htm ZHANG Y, LIANG N, SUN H. Cytokines and papillary thyroid carcinoma: from molecular mechanism to clinical application[J]. Chinese Journal of Laboratory Diagnosis, 2022, 26(1): 117-120. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD202201035.htm
[9]	HU J Q, LEI B W, WEN D, et al. IL-2 enhanced MHC class Ⅰ expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape in vitro[J]. J Cancer, 2020, 11(14): 4250-4260.
[10]	李娜, 连续. IL-12与Th17在自身免疫性甲状腺疾病中的研究进展[J]. 牡丹江医学院学报, 2020, 41(6): 139-142. https://www.cnki.com.cn/Article/CJFDTOTAL-MDJB202006039.htm LI N, LIAN X. Research progress of IL-12 and TH17 in autoimmune thyroid disease[J]. Journal of Mudanjiang Medical University, 2020, 41(6): 139-142. https://www.cnki.com.cn/Article/CJFDTOTAL-MDJB202006039.htm
[11]	NGUYEN K G, VRABEL M R, MANTOOTH S M, et al. Localized interleukin-12 for cancer immunotherapy[J]. Front Immunol, 2020, 15(11): 575597. DOI: 10.3389/fimmu.2020.575597.
[12]	曹纪萍, 赵艳峰, 张亚民, 等. EB病毒感染及XRCC1、IL-10基因多态性与甲状腺癌的关联性分析[J]. 现代生物医学进展, 2023, 23(12): 2371-2376. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX202312032.htm CAO J P, ZHAO Y F, ZHANG Y M, et al. Association of EB Virus Infection and Gene Polymorphisms of XRCC1 and IL-10 with Thyroid Cancer[J]. Progress in Modern Biomedicine, 2023, 23(12): 2371-2376. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX202312032.htm
[13]	代毅, 陈昱幸子, 陈勇, 等. 血清IL-2、IL-6、IL-10与分化型甲状腺癌诊断及侵袭性的相关性分析[J]. 现代实用医学, 2023, 35(5): 620-622, 701. https://www.cnki.com.cn/Article/CJFDTOTAL-NBYX202305018.htm DAI Y, CHEN Y X Z, CHEN Y, et al. Serum levels of IL-2, IL-6 and Il-10 were correlated with the diagnosis and invasiveness of differentiated thyroid cancer[J]. Modern Practical Medicine, 2023, 35(5): 620-622, 701. https://www.cnki.com.cn/Article/CJFDTOTAL-NBYX202305018.htm
[14]	LU Z W, HU J Q, LIU W L, et al. IL-10 restores MHC Class Ⅰ expression and interferes with immunity in papillary thyroid cancer with hashimoto thyroiditis[J]. Endocrinology, 2020, 161(10): bqaa062. DOI: 10.1210/endocr/bqaa062.
[15]	王惟, 张达容, 黄煜琪, 等. 甲状腺癌患者血清IL-17、IL-35、SIL-2R表达水平及其临床意义[J]. 现代生物医学进展, 2018, 18(4): 729-732. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201804028.htm WANG W, ZHANG D R, HUANG Y Q, et al. Expressions and Clinical Significance of Serum IL-17, IL-35 and SIL-2R in Patients with Thyroid Cancer[J]. Progress in Modern Biomedicine, 2018, 18(4): 729-732. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201804028.htm
[16]	OZISIK H, CEKIN A, SUNER A, et al. Evaluation of IL-10, MCP-1, IFN gamma, and protectin D1 levels in patients with Hashimoto's thyroiditis[J]. Ir J Med Sci, 2023, 192(1): 177-184.
[17]	ARAQUE K A, GUBBI S, KLUBO-GWIEZDZINSKA J. Updates on the management of thyroid cancer[J]. Horm Metab Res, 2020, 52(8): 562-577.
[18]	朱光亮, 沈俊, 李晓明, 等. 美洛昔康预处理联合超声引导下喉上神经阻滞在甲状腺癌手术患者围术期中的应用[J]. 中华全科医学, 2022, 20(3): 391-394. doi: 10.16766/j.cnki.issn.1674-4152.002360 ZHU G L, SHEN J, LI X M, et al. Application of meloxicam pretreatment combined with ultrasound-guided internal branch of superior laryngeal nerve block in perioperative period of radical thyroidectomy patients[J]. Chinese Journal of General Practice, 2022, 20(3): 391-394. doi: 10.16766/j.cnki.issn.1674-4152.002360